Dishman Pharmaceuticals and Chemicals Limited News and Updates

Name: Latest research reports of Dishman Pharmaceuticals and Chemicals Limited authored by BP Wealth and published by - Trendlyne research reports.
Item: Dishman Pharmaceuticals and Chemicals Limited
Rating: 5
Author: BP Wealth

Keep track of all breaking news on Dishman Pharmaceuticals and Chemicals Limited from all sources in a single place.

Dishman Pharmaceuticals and Chemicals Limited

21 Oct 2021, 03:33PM

Dishman Group to invest $50 mn for setting up drug manufacturing facility

Business Standard

As part of its expansion plans, the Gujarat-headquartered drug developer will invest $50 million in France

Dishman Pharmaceuticals and Chemicals Limited

15 Apr 2020

BP Equities Pharmaceuticals Result Preview Q4 FY20

Buy: Dishman Pharmaceuticals an...

Target

BP Wealth

We expect the companies under our pharmaceuticals coverage to report revenue growth of ~6% in Q4FY20 with 14.2% growth in profitability, driven by strong traction in India and API business. The US revenues are expected to decline by 1.6% YoY mainly due to high base and lack of meaningful launches. However, strong ramp-up in gTamiflu and steady base business performance in some US focused players due to potential increase in stocking at the wholesaler level can surprise on the positive side. With respect to domestic markets, the growth is likely to favour companies with larger presence in acute therapy led by extended acute season. Growth in other emerging markets and Europe is likely to be driven by new launches. The recent INR weakness will also benefit Indian pharma companies, but some of the margin benefit is being offset from EM currencies and higher API...

Dishman Pharmaceuticals and Chemicals Limited

25 Jan 2019

Dishman Pharma: Margins and PAT above expectation

Buy: Dishman Pharmaceuticals an...

Target

Karvy

Margins and PAT above expectation: Total Revenues for the quarter grew by 4.2% to Rs 4274 mn, which includesRs 516 mn of other operating income. EBITDA was up by 9.1% YoY to Rs1327 mn on account of better gross margins.

Dishman Pharmaceuticals and Chemicals Limited

28 Jan 2018

Your Taxes

Business Line

I had bought 100 shares of Dishman Pharma on October 8, 2012 and again 200 shares on July 29, 2013 through the stock exchange. The company issued bonus shares in the ra

Dishman Pharmaceuticals and Chemicals Limited

18 May 2017

BP Equities Dishman Pharma Ltd Q4FY17 Result Upda

Buy: Dishman Pharmaceuticals an...

BP Wealth

Vitamin D analogues and cholesterol. EBITDA margins expanded from 24.8% to 27.5% (est.27%) on a YoY basis above our estimate mainly due to Carbogen Amcis and Vitamin D business saw upsurge in EBITDA margins.Q4 FY17 PAT decreased by 14% YoY to Rs. 428mn came below our estimate due to Sector Outlook...

Dishman Pharmaceuticals and Chemicals Limited

29 Mar 2017

Dishman Pharma Surges Nearly 40% In Two Sessions

NDTV Profit

Shares of Dishman Pharma came in huge demand in opening deals in today's session. On Bombay Stock Exchange alone 1.52 million shares changed hands.

Dishman Pharmaceuticals and Chemicals Limited

28 Mar 2017

Dishman Pharma hits all-time high on USFDA nod to cancer drug

Business Standard

Reacting to the development, the stock rallied as much as 20% to Rs 278

Dishman Pharma shares hit all-time high on FDA nod for cancer drug

Business Line | 28 Mar 2017

Dishman Pharmaceuticals and Chemicals Limited

08 Mar 2017

Fire at Dishman Pharma Bavla unit

Business Line

Dishman Pharmaceuticals and Chemicals Ltd today said there was fire at one of the units of its Bavla facility on Tuesday evening. There was a fire incident at one of the units (Unit No.7) at our...

Dishman Pharmaceuticals and Chemicals Limited

06 Mar 2017

Result Updates

Sell: Dishman Pharmaceuticals an...

Angel Broking

Dishman Pharmaceuticals posted results lower than expected for 3QFY2017, with sales at Rs356cr v/s. Rs386cr in 3QFY2016, down by 7.6% yoy, mainly on the back of CRAMS. CRAMS sales (Rs246.7cr) de-grew by 16.5% yoy, constituting 69.2% of sales in 3QFY2017; while others (Rs110cr) posted a growth of 21.2% yoy. On the operating front, the gros..

Dishman Pharmaceuticals and Chemicals Limited

15 Feb 2017

BP Equities Dishman Pharma Ltd Q3FY17 Result Upda

Buy: Dishman Pharmaceuticals an...

BP Wealth

logues and cholesterol. EBITDA margins declined from 28.3% in to 26.4% (est.26.7%) on a YoY basis slightly below our estimate mainly due to CRAMS UK and other marketable molecules saw a decline in EBITDA margins.Q3 FY17 PAT increased by 8% YoY to Rs. 547mn came inline with our estimate of Sector Outlook Rs. 547mn due to higher other income (foreign currency gains). Interest expense declined by 27.5% YoY in Q3 FY17 driven by lower debt, conversion of rupee debt into foreign debt. Hence, PAT margin Stock...

Is Dishman Pharmaceuticals and Chemicals Limited worth buying?

12 Votes:

Buy 75.0%

Sell 16.67%

Hold 8.33%